Skip to main content

Table 3 Summary of LSM and fibrosis stages according to CXCL9-11 polymorphisms (CXCL9 rs10336, CXCL10 rs3921, and CXCL11 rs4619915) in HCV-infected patients

From: CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study

rs10336 AA AG GG pa
No. 64 193 132  
LSM (kPa) 8.6 (6.1; 12.9) 6.7 (5.3; 8.9) 7.5 (5.6; 11.7) 0.002
 F ≥ 2 (≥7.1) 40 (62.5%) 77 (39.9%) 67 (50.8%) 0.004
 F ≥ 3 (≥9.5) 28 (43.8%) 44 (22.8%) 47 (35.6%) 0.002
 F4 (≥12.5) 17 (26.6%) 26 (13.5%) 28 (21.2%) 0.035
rs3921 CC CG GG pa
No. 63 191 135  
LSM (kPa) 8.6 (6.1; 12.9) 6.7 (5.3; 9.1) 7.6 (5.6; 11.6) 0.001
 F ≥ 2 (≥7.1 kPa) 39 (61.9%) 75 (39.3%) 70 (51.9%) 0.003
 F ≥ 3 (≥9.5 kPa) 28 (44.4%) 44 (23%) 47 (34.8%) 0.003
 F4 (≥12.5 kPa) 17 (27%) 26 (13.6%) 28 (20.7%) 0.038
rs4619915 AA AG GG pa
No. 63 191 135  
LSM (kPa) 8.6 (6.1; 12.9) 6.7 (5.3; 9.1) 7.6 (5.6; 11.6) 0.001
 F ≥ 2 (≥ 7.1) 39 (61.9%) 75 (39.3%) 70 (51.9%) 0.003
 F ≥ 3 (≥ 9.5) 28 (44.4%) 44 (23.0%) 47 (34.8%) 0.003
 F4 (≥ 12.5) 17 (27%) 26 (13.6%) 28 (20.7%) 0.038
  1. p value level of significance LSM liver stiffness measure, kPa kilopascal, F  2 significant fibrosis, F  3 advance fibrosis, F4 cirrhosis, CXCL chemokine (C-X-C motif) ligand
  2. Statistical: a p values were calculated by KW (continuous variable) or Chi squared test (dichotomous variable). Statistically significant differences are shown in italic